Research analysts at StockNews.com assumed coverage on shares of AcelRx Pharmaceuticals (NASDAQ:ACRX – Get Free Report) in a research note issued on Sunday. The brokerage set a “sell” rating on the specialty pharmaceutical company’s stock.
AcelRx Pharmaceuticals Stock Down 5.5 %
ACRX stock opened at $1.21 on Friday. The firm has a 50 day moving average of $1.04 and a 200 day moving average of $1.26. The stock has a market capitalization of $13.21 million, a PE ratio of 0.18 and a beta of 0.24. AcelRx Pharmaceuticals has a 52 week low of $0.55 and a 52 week high of $7.60.
Hedge Funds Weigh In On AcelRx Pharmaceuticals
Several large investors have recently made changes to their positions in ACRX. Renaissance Technologies LLC acquired a new position in shares of AcelRx Pharmaceuticals in the 1st quarter valued at $27,000. Virtu Financial LLC purchased a new stake in AcelRx Pharmaceuticals in the 2nd quarter worth $29,000. Susquehanna International Group LLP purchased a new stake in AcelRx Pharmaceuticals in the 4th quarter worth $144,000. BlackRock Inc. increased its holdings in AcelRx Pharmaceuticals by 1.0% in the 3rd quarter. BlackRock Inc. now owns 1,947,140 shares of the specialty pharmaceutical company’s stock worth $407,000 after acquiring an additional 19,986 shares in the last quarter. Finally, Armistice Capital LLC purchased a new stake in AcelRx Pharmaceuticals in the 4th quarter worth $830,000. 10.04% of the stock is currently owned by institutional investors and hedge funds.
AcelRx Pharmaceuticals Company Profile
AcelRx Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA and DZUVEO, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company develops ZALVISO, a patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain; ARX-02, which is in Phase 2 clinical trial for the treatment of cancer breakthrough pain in opioid-tolerant patients; and ARX-03, which is in Phase 2 clinical trial for the treatment of procedural anxiety and acute pain.
Featured Stories
- Five stocks we like better than AcelRx Pharmaceuticals
- MarketBeat Week in Review – 7/10 – 7/14
- Wells Fargo’s Earnings, Why Markets Are Loving The Stock
- Citigroup Leads Banking Earnings, What’s Next?
- BlackRock Kicks Off Financials Earnings Season, Gauge To Markets
- JPMorgan Chase Is In Reversal But Don’t Chase It Higher
Receive News & Ratings for AcelRx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AcelRx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
